Aytu Biopharma, Inc. Announces Resignation of Richard I. Eisenstadt as Chief Financial Officer, Effective December 30, 2021
December 13, 2021 at 06:02 am
Share
On December 8, 2021, Richard I. Eisenstadt resigned as Chief Financial Officer of Aytu BioPharma, Inc. (the Company"), effective December 30, 2021, to pursue another opportunity at a development-stage pharmaceutical company. Mr. Eisenstadt's resignation is not due to any outstanding issues with the Company or disagreements with respect to the Company's operations, policies or practices, or the Company's independent auditors. The Company has initiated a search to identify and recruit a new candidate for the role of Chief Financial Officer.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
AYTU BIOPHARMA, INC. 
